Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 93« First...34567...102030...Last »

Aquinox to stop development of lead drug

Aquinox Pharmaceuticals Inc. plans to stop developing its main drug to treat bladder pain syndrome as rosiptor failed to meet the main goal of a late-stage trial, pushing the company’s shares down as much as 85 percent.

Read More »

AstraZeneca, Merck eye $1 billion boost from cancer drug success

AstraZeneca’s oncology business received a boost as results of a clinical trial showed the company’s drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

Read More »

Modified polio vaccine extends lives in U.S. brain cancer study

Some 21 percent of patients with advanced brain cancer treated with a modified polio vaccine were alive after three years, compared with 4 percent with similar tumors who received standard therapies.

Read More »

Breast cancer drug combo falls short of survival goal

A combination of Pfizer’s breast cancer medicine Ibrance and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.

Read More »

Lilly’s Jardiance meets main goal of two diabetes trials

Eli Lilly and Co.’s Jardiance, along with insulin therapy, met the main goal of two trials testing the company’s drug in patients with type 1 diabetes.

Read More »

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc. will stop developing the company’s experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Read More »

Study preserves hopes for Roche’s Tecentriq in lung cancer

A clinical trial showed positive survival data for Swiss drugmaker Roche’s potential immunotherapy cocktail as an initial treatment for an aggressive form of lung cancer.

Read More »

Trends and Challenges in Fibromyalgia Drug Research

Growth in fibromyalgia drug research over the past five years has made site selection a far less taxing prospect. There are now hundreds of sites capable of performing this research, and the challenge is to gather current feedback on them.

Read More »

UroGen to start mid-stage bladder cancer trial

UroGen Pharma plans to begin a mid-stage trial of the company’s treatment for bladder cancer patients after positive interim results from an advanced trial of a treatment for upper urinary tract cancer.

Read More »

Latecomer Sanofi looks to catch next wave of cancer therapies

Sanofi hired John Reed, the former top scientist at oncology market leader Roche, to head the drugmaker’s group research operations.

Read More »

Anika Reports Results from Knee Osteoarthritis Study

Anika Therapeutics Inc. announced results from the company’s CINGAL 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration.

Read More »

Sarepta gene therapy study shows promise

Sarepta Therapeutics shares jumped 60 percent after reporting promising results from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD).

Read More »

FDA declines to approve Valeant’s plaque psoriasis lotion

Valeant Pharmaceuticals International Inc.’s plaque psoriasis treatment did not get approval from U.S. health regulators.

Read More »

Teva to discontinue study for chronic headache treatment

Teva Pharmaceutical Inc. will discontinue a trial testing the company’s drug for the treatment of chronic cluster headache.

Read More »

New research points to universal antibody drug for HIV

AIDS researchers in Hong Kong say new research – tested on mice – indicates a functional cure for HIV, eventually leading to a new antibody that could be used for prevention and treatment.

Read More »

Novartis touts effectiveness, safety of autoimmune drug copies

Novartis touted safety and efficacy of the company’s biosimilar copies of Johnson & Johnson’s Remicade and Amgen’s Enbrel for treating autoimmune diseases.

Read More »

GSK’s two-drug HIV treatment meets studies’ main goal

GlaxoSmithKline’s two-drug treatment for HIV met its main goal in late-stage studies, scoring key points in the company’s rivalry with Gilead in the medical field.

Read More »

Lilly’s lupus treatment succeeds in mid-stage trial

Eli Lilly and Co. said the company’s drug to treat the autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a larger study in 2018.

Read More »

Flex Pharma Shutters Phase II ALS Program

Boston-based Flex Pharma announced the closing of a Phase II clinical trial of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT).

Read More »

Lilly-AstraZeneca abandon Alzheimer’s drug trials

Eli Lilly and AstraZeneca discontinued late-stage trials testing their Alzheimer’s treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

Read More »

Page 5 of 93« First...34567...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom